Ad4-Env145NFL / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2026 ➔ Nov 2028 | Trial primary completion date: Oct 2026 ➔ Nov 2028

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2025 ➔ Oct 2025 | Trial primary completion date: Apr 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4